Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Fachinformation Verzenios® (Abemaciclib) Pflichttext Verzenios® (Abemaciclib) Januar 2026 Ficha Técnica Verzenios® (Abemaciclib)
touchMEETING HIGHLIGHTS

Managing breast cancer with CDK 4/6 inhibition: the long-term efficacy and safety of abemaciclib

Topics Covered:
Breast Cancer
Open Nav

Videos

Abemaciclib plus endocrine therapy for early breast cancer: 7-year survival data from monarchE

In this video, Prof. Stephen Johnston discusses monarchE 7-year data for HR+, HER2- node-positive, high-risk early breast cancer.
Prof. Stephen Johnston
Duration: 5:18

Managing adverse events with abemaciclib: dose reduction strategies in patients with early breast cancer

In this video, Prof. Stephen Johnston discusses long term safety profile of abemaciclib and ways to manage toxicity including dose reduction.
Prof. Stephen Johnston
Duration: 5:50

Abemaciclib in metastatic breast cancer: long-term efficacy from MONARCH 3 and MONARCH 2

In this video, Prof. Patrick Neven discusses updated results from the MONARCH 3 and MONARCH 2 trials with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer.
Prof. Patrick Neven
Duration: 2:58

Overview of the long-term efficacy and safety of abemaciclib in breast cancer

In this video, Prof. Valentina Guarneri provides an overview of the long-term efficacy and safety of abemaciclib in patients with HR+, HER2- node-positive, high-risk early breast cancer and metastatic breast cancer.
Prof. Valentina Guarneri
Duration: 2:13
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Videos

Abemaciclib plus endocrine therapy for early breast cancer: 7-year survival data from monarchE

In this video, Prof. Stephen Johnston discusses monarchE 7-year data for HR+, HER2- node-positive, high-risk early breast cancer.
Prof. Stephen Johnston
Duration: 5:18

Managing adverse events with abemaciclib: dose reduction strategies in patients with early breast cancer

In this video, Prof. Stephen Johnston discusses long term safety profile of abemaciclib and ways to manage toxicity including dose reduction.
Prof. Stephen Johnston
Duration: 5:50

Abemaciclib in metastatic breast cancer: long-term efficacy from MONARCH 3 and MONARCH 2

In this video, Prof. Patrick Neven discusses updated results from the MONARCH 3 and MONARCH 2 trials with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer.
Prof. Patrick Neven
Duration: 2:58

Overview of the long-term efficacy and safety of abemaciclib in breast cancer

In this video, Prof. Valentina Guarneri provides an overview of the long-term efficacy and safety of abemaciclib in patients with HR+, HER2- node-positive, high-risk early breast cancer and metastatic breast cancer.
Prof. Valentina Guarneri
Duration: 2:13

Activity Overview

Faculty & Disclosures

Activity Overview
Faculty & Disclosures

Overview

In this activity, we will explore the role of abemaciclib, an oral CDK4/6 inhibitor that offers sustained clinical benefit for patients with HR+, HER2- node-positive, high-risk early breast cancer and metastatic breast cancer. In high-risk, early-stage breast cancer, the monarchE trial demonstrated that adding abemaciclib to adjuvant endocrine therapy improved overall survival and reduced the risk of invasive disease recurrence compared with endocrine therapy alone.1-3 In the metastatic setting, MONARCH 3 showed that first-line treatment with abemaciclib plus a nonsteroidal aromatase inhibitor lowered the risk of disease progression and produced clinically meaningful, not statistically significant overall survival gains.2 For patients whose disease progressed on prior endocrine therapy, MONARCH 2 demonstrated a statistically significant overall survival advantage with abemaciclib combined with fulvestrant.3 Across these pivotal studies, abemaciclib consistently showed a manageable safety profile, with adverse events generally low grade and managed through proactive supportive care and dose adjustments without compromising efficacy.4

Learning Objectives

After watching this activity, participants should be better able to:

  • Gain insights into the monarchE 7-year overall survival data in HR+, HER2-, node-positive, high-risk early breast cancer
  • Describe the abemaciclib plus endocrine therapy regimens used in different breast cancer settings
  • Understand how to manage abemaciclib dosing in patients experiencing adverse events

References4

List View
Grid View
1

Johnston S, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155–165.

2

Goetz MP, Toi M, Huober J, et al. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol. 2024;35:718–27.

3

Sledge GW, Jr., Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–24.

4

Rugo HS, O’Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33:616–27.

Faculty & Disclosures3

Prof. Stephen Johnston

Royal Marsden NHS Foundation Trust, London, UK
More Information
Close Popup

Prof. Stephen Johnston

Royal Marsden NHS Foundation Trust, London, UK
UK

Biography

Stephen Johnston is Head of Medical Oncology, Head of the Breast Unit and Professor of Breast Cancer Medicine at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He also serves as Clinical Director of the Breast, Lung and AOS Clinical Business Unit at The Royal Marsden. His clinical and research focus is metastatic breast cancer, particularly mechanisms of endocrine resistance, and he is chief investigator of multiple phase II/III trials of novel endocrine and targeted therapies. He has authored over 250 peer-reviewed publications, is a frequent international speaker, and holds key roles on scientific committees and editorial boards, including as Deputy/Associate Editor of Breast Cancer Research and Clinical Breast Cancer.

Disclosures

Advisory fees from Eli Lilly, Novartis, Pfizer, Puma Biotechnology, Novartis, and Sanofi Genzyme. Honoraria from AstraZeneca, Eli Lilly, Novartis Eisai, Pfizer, Roche-Genentech, and Sanofi Genzyme. Research funding from AstraZeneca, Eli Lilly, Novartis, Pfizer, Puma Biotechnology, and Roche-Genentech.

Prof. Valentina Guarneri

Prof. Patrick Neven

Prof. Patrick Neven

University Hospitals Leuven, Louvain, Belgium
More Information
Close Popup

Prof. Patrick Neven

University Hospitals Leuven, Louvain, Belgium
Belgium

Biography

Patrick Neven is a professor of gynaecological oncology at University Hospitals Leuven and a member of the Multidisciplinary Breast Centre. His research focuses on endocrine therapy in breast cancer, and he has served as principal investigator on numerous clinical trials. He has published extensively, is a frequent national and international speaker, and holds leadership roles in scientific societies, including President of the Belgian Society of Senology.

Disclosures

Honoraria from AstraZeneca, Eli Lilly, Gilead, Menarini, Novartis, Pfizer, and Roche. Travel support from AstraZeneca, Eli Lilly, Novartis, Pfizer, and Roche.

Prof. Stephen Johnston

Prof. Valentina Guarneri

Prof. Valentina Guarneri

University of Padua, Padua, Italy
More Information
Close Popup

Prof. Valentina Guarneri

University of Padua, Padua, Italy
Italy

Biography

Valentina Guarneri is a professor of oncology at the University of Padua, Head of Oncology Division 2 at the Istituto Oncologico Veneto, and head of the Specialization School in Medical Oncology at the University of Padua. Her research focuses on clinical and translational breast cancer research, and she has authored more than 200 peer-reviewed publications.

Disclosures

Advisory fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Menarini Stemline, MSD, Novartis, Olema Oncology, Pfizer, Pierre Fabre, and Roche. Speaker fees from AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, GSK, Menarini Stemline, Novartis, Roche, and Zentiva. Expert testimony fees from Eli Lilly.

Prof. Patrick Neven

Prof. Stephen Johnston

Video Navigation

Videos

Abemaciclib plus endocrine therapy for early breast cancer: 7-year survival data from monarchE

In this video, Prof. Stephen Johnston discusses monarchE 7-year data for HR+, HER2- node-positive, high-risk early breast cancer.
Prof. Stephen Johnston
Duration: 5:18

Managing adverse events with abemaciclib: dose reduction strategies in patients with early breast cancer

In this video, Prof. Stephen Johnston discusses long term safety profile of abemaciclib and ways to manage toxicity including dose reduction.
Prof. Stephen Johnston
Duration: 5:50

Abemaciclib in metastatic breast cancer: long-term efficacy from MONARCH 3 and MONARCH 2

In this video, Prof. Patrick Neven discusses updated results from the MONARCH 3 and MONARCH 2 trials with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer.
Prof. Patrick Neven
Duration: 2:58

Overview of the long-term efficacy and safety of abemaciclib in breast cancer

In this video, Prof. Valentina Guarneri provides an overview of the long-term efficacy and safety of abemaciclib in patients with HR+, HER2- node-positive, high-risk early breast cancer and metastatic breast cancer.
Prof. Valentina Guarneri
Duration: 2:13

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchMEETING HIGHLIGHTS

This content is intended for healthcare professionals in Brazil, Germany and Spain only.

Please confirm that you are a healthcare professional in one of those countries.

Continue
Decline

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Close Popup
touchONCOLOGY
touchMEETING HIGHLIGHTS

Access to this content is only permitted for healthcare professionals in Brazil, Germany and Spain.

Back to touchONCOLOGY
Close Popup
touchONCOLOGY
touchMEETING HIGHLIGHTS

This content is intended for healthcare professionals in Brazil, Germany and Spain only.

Please confirm that you are a healthcare professional in one of those countries.

Register
Login

To access this content.

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Close Popup
touchONCOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

No endorsement by Eli Lilly or TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

The views and opinions expressed are those of the faculty and do not necessarily reflect those of any sponsor.

° Ein statistisch signifikanter OS-Vorteil wurde in der ITT-Population beobachtet, hauptsächlich beeinflusst durch die zulassungsrelevante Kohorte 1 (91 % der ITT). Verzenios® ist für Kohorte 1 zugelassen; die OS-Analyse in dieser Subgruppe war jedoch weder auf Signifikanz gepowert noch alpha-kontrolliert. Nach der primären IDFS-Analyse wurde der OS-Analyseplan nach Rücksprache mit den Zulassungsbehörden geändert, um die Anzahl der finalen Ereignisse von 390 auf 650 zu erhöhen und so eine Nachbeobachtungszeit von ≥ 5 Jahren sicherzustellen.1,2

1. Johnston S, Martin M, O’Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155–165. doi:10.1016/j.annonc.2025.10.005

2. Rastogi P, O’Shaughnessy J, Martin M, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol. 2024;42(9):987-993. doi:10.1200/JCO.23.01994

3. Fachinformation Verzenios® (aktueller Stand)

Verzenios® ist in Kombination mit einer ET angezeigt für die adjuvante Behandlung von erwachsenen Patient:innen mit Hormonrezeptor (HR)-positivem, humanem epidermalen Wachstumsfaktor-Rezeptor-2 (HER2)-negativem, nodal-positivem Brustkrebs im frühen Stadium mit einem hohen Rezidivrisiko#. Bei prä- oder perimenopausalen Frauen sollte die endokrine Aromatasehemmer-Therapie mit einem LHRH-Agonisten (LHRH = Luteinising Hormone Releasing Hormone) kombiniert werden.

* = Indication text for Verzenios in eBC

# = Hohes Rezidivrisiko definiert als ≥ 4 positive axilläre Lymphknoten oder 1–3 positive axilläre Lymphknoten und mind. eins der folgenden Kriterien: Tumorgröße ≥ 5 cm oder histologischer Grad 3.3

CMAT-13172. März/2026

Art. 42 Any support or sponsorship, whether full or partial, provided to healthcare professionals for participation in scientific events, national or international, must not be conditioned upon the prescription, dispensing, and/or promotion or advertising of any type of medication.
Material destinado exclusivamente a profissionais de saúde com habilitação para dispensar e prescrever medicamentos.
PP-AL-BR-1821. Março/2026

PP-AL-ES-1483. Marzo/2026

Latest articles videos and clinical updates - straight to your inbox

Close Popup